Analysts forecast that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will report earnings of ($0.03) per share for the current quarter, according to Zacks. Eight analysts have issued estimates for Neurocrine Biosciences’ earnings, with estimates ranging from ($0.79) to $0.39. Neurocrine Biosciences reported earnings of ($0.51) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 94.1%. The company is expected to announce its next earnings results on Tuesday, February 13th.

According to Zacks, analysts expect that Neurocrine Biosciences will report full year earnings of ($1.74) per share for the current financial year, with EPS estimates ranging from ($2.52) to ($1.31). For the next fiscal year, analysts expect that the business will post earnings of ($0.37) per share, with EPS estimates ranging from ($1.58) to $2.00. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same quarter last year, the business earned ($0.43) EPS.

Several research analysts recently commented on NBIX shares. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $70.00 target price on shares of Neurocrine Biosciences in a report on Thursday, September 7th. Jefferies Group LLC reiterated a “buy” rating and issued a $69.00 target price (up previously from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. ValuEngine upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BMO Capital Markets reiterated an “outperform” rating and issued a $84.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 5th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $66.00 target price on shares of Neurocrine Biosciences in a report on Thursday, September 21st. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $78.88.

In other news, insider Christopher Flint Obrien sold 52,817 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $57.50, for a total transaction of $3,036,977.50. Following the sale, the insider now directly owns 101,790 shares in the company, valued at approximately $5,852,925. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kyle Gano sold 24,818 shares of Neurocrine Biosciences stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total transaction of $1,763,318.90. Following the sale, the insider now owns 84,596 shares in the company, valued at $6,010,545.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 110,810 shares of company stock worth $6,797,998. 4.80% of the stock is owned by company insiders.

Several institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its position in shares of Neurocrine Biosciences by 14.5% during the 3rd quarter. Wells Fargo & Company MN now owns 945,368 shares of the company’s stock valued at $57,931,000 after acquiring an additional 119,383 shares in the last quarter. Schroder Investment Management Group boosted its position in shares of Neurocrine Biosciences by 81.0% during the 3rd quarter. Schroder Investment Management Group now owns 37,105 shares of the company’s stock valued at $2,204,000 after acquiring an additional 16,609 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at about $246,000. Legal & General Group Plc boosted its position in shares of Neurocrine Biosciences by 14.6% during the 3rd quarter. Legal & General Group Plc now owns 36,497 shares of the company’s stock valued at $2,237,000 after acquiring an additional 4,638 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at about $1,457,000.

Shares of Neurocrine Biosciences (NASDAQ NBIX) traded up $0.04 on Friday, reaching $75.46. 768,500 shares of the company traded hands, compared to its average volume of 1,130,864. Neurocrine Biosciences has a 12-month low of $37.35 and a 12-month high of $75.98. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05.

COPYRIGHT VIOLATION NOTICE: “Analysts Expect Neurocrine Biosciences, Inc. (NBIX) to Announce -$0.03 EPS” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/analysts-expect-neurocrine-biosciences-inc-nbix-to-announce-0-03-eps/1696748.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.